A critical look at neuroscience - the clinical trials, the research studies, how it affects our daily life, and the claims that deserve a closer read.
Live Last read · last published · next check
A Nature Medicine study of 2.5 million people found 26 genetic risk variants for fibromyalgia — including the Huntington's disease gene (HTT). Then it answered questions its data couldn't support.
"Failed" has at least eight meanings, and the differences among them are everything. A working guide to reading a negative trial — and why only one kind of failure tells you the science was wrong.
Cold plunges, humming, gargling, ear-clip "vagus nerve stimulation": what actually reaches the nerve, what the real (FDA-approved) devices do, and why the nerve was never the problem.
Biogen's tau ASO hit its biomarkers and missed its primary at AAIC — and the clinical signal was largest at the lowest dose. The safety explains why.
The body doesn't wait to find out what's real. It acts on what it expects - and sometimes what it expects is wrong.
Four programs, one genuine topline, and a lesson in telling a first-time readout apart from a well-dressed update.
The first time I fainted, I was a medical student dissecting a vagus nerve. What happened in my body that day was older than humans — and it had nothing to do with me being weak.
The digital biomarker field has spent two decades building more sensitive instruments. The FDA keeps asking a different question entirely.
A Stanford sleep-lab test and the scientific literature reveal which wearable claims are well validated—and which remain mostly educated guesses.
The number 10,000 came from a 1960s Japanese pedometer ad. The number 9,826 came from a single observational study that can't prove what the headlines claim. Here's what the evidence actually supports
Two Parkinson's drugs moved their key biomarkers in the wrong direction. Both companies reframed the result as confirmatory. One program has already failed. The other is still running.
BIIB122 missed every endpoint despite >90% peripheral kinase inhibition. The reasons matter for the LRRK2 hypothesis, for the Ionis ASO that worked better, and for where PD drug development goes next
It's not random. As alcohol clears, five biological systems snap back at once; and the same machinery wakes the people who never touched a drink.
Biogen's tau-targeting ASO slowed AD cognitive decline "comparable to approved amyloid-targeting therapies." But the trial was halved mid-enrollment and no actual numbers have been released.
A Nature paper claims your brain ages fastest at 6.42 hours. The entire finding rests on one subjective survey question — answered in whole hours.
A Recent Meta-Analysis Concludes Amyloid-Targeted Therapies Offer Little Clinical Benefit in Alzheimer’s Disease. The Analysis Has Critical Limitations.
Two Nature papers last year, a recent approval in Japan, and the unanswered question of whether neuron replacement will truly change PD
A nationwide natural experiment using clinical trial emulation shows that discontinuing cholinesterase inhibitors accelerates cognitive decline in Alzheimer’s patients
A single short infusion produced a large antidepressant effect at 2 weeks. The biology is intriguing. The bar remains high.
Big tech is building continuous physiological telemetry. Emotional certainty is another matter.
